INVO Bioscience (NASDAQ:INVO) Upgraded to "Buy" by Zacks Investment Research
Zacks Investment Research upgraded shares of INVO Bioscience (NASDAQ:INVO – Get Rating) from a hold rating to a buy rating in a report issued on Friday morning, Zacks.com reports. They currently have $2.25 price objective on the stock. According to Zacks, “INVO Bioscience is a medical device company, headquartered in Beverly, Massachusetts, focused on creating […]